+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID03896568

Evaluating Stem Cell-Delivered Oncolytic Adenovirus DNX-2401 via Intra-Arterial Injection for Recurrent High-Grade Glioma Treatment

Led by M.D. Anderson Cancer Center · Updated on 2026-09-25

36

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the best dose and side effects of a treatment using allogeneic bone marrow-derived human mesenchymal stem cells BM-hMSCs loaded with an oncolytic adenovirus called DNX-2401. This study focuses on patients with recurrent high-grade glioma, including glioblastoma, gliosarcoma, and certain types of astrocytoma, aiming to determine how this treatment targets brain cancer cells and its safety when administered intra-arterially. Participants receive the study treatment through one or two infusions of BM-hMSCs-DNX-2401 via transfemoral endovascular intracranial injection. The trial has two parts Part I involves dose escalation with one or two infusions Part II includes surgery to remove the tumor followed by intramural injection of the treatment into the resection cavity. Treatment and follow-up visits are scheduled intensively after infusions and continue for up to several years to monitor tumor progression and treatment effects. During the study, participants undergo multiple assessments including MRI scans, blood and sputum tests for virus shedding, antibody tests, and evaluations of immune response and tumor tissue after surgery. Researchers measure maximum tolerated dose, adverse events, tumor response, progression-free survival, and overall survival. Follow-up visits occur frequently after treatment and extend until tumor growth is observed, ensuring careful monitoring of safety and treatment outcomes.

CONDITIONS

Brief Title

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Research Team

F

Frederick Lang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here